Yang Lin, Zhang Hanyin, Chen Dan, Ding Peikun, Yuan Yunchang, Zhang Yandong
Department of Thoracic Surgery, Shenzhen People's Hospital, 2nd Clinical Medical College of Jinan University, Shenzhen, China.
Department of Biology, Southern University of Science and Technology, Shenzhen, China.
Gene. 2018 Feb 5;642:95-102. doi: 10.1016/j.gene.2017.11.029. Epub 2017 Nov 10.
Oncogenes EGFR and ras are frequently mutated and activated in human lung cancers. In this report, we found that both EGFR and Ras signaling can upregulate RNA helicase DDX59 in lung cancer cells. DDX59 can be induced through the mitogen activated protein kinase (MAPK) pathway after EGFR or Ras activation. Inhibitors for Ras/Raf/MAP pathway significantly decreased DDX59 expression at both protein and mRNA levels. Through immunohistochemistry, we found that DDX59 protein expression correlated with Ras and EGFR mutation status in human lung adenocarcinoma. Finally, through a xenograft nude mice model, we demonstrated that DDX59 is pivotal for EGFR mutated lung cancer cell growth in vivo. Our study identified a novel protein downstream of Ras and EGFR, which may serve as a potential therapeutic drug target for lung cancer patients.
癌基因EGFR和ras在人类肺癌中经常发生突变并被激活。在本报告中,我们发现EGFR和Ras信号传导均可上调肺癌细胞中的RNA解旋酶DDX59。EGFR或Ras激活后,DDX59可通过丝裂原活化蛋白激酶(MAPK)途径诱导产生。Ras/Raf/MAP途径抑制剂在蛋白质和mRNA水平上均显著降低了DDX59的表达。通过免疫组织化学,我们发现DDX59蛋白表达与人类肺腺癌中的Ras和EGFR突变状态相关。最后,通过异种移植裸鼠模型,我们证明了DDX59对体内EGFR突变的肺癌细胞生长至关重要。我们的研究鉴定出一种Ras和EGFR下游的新型蛋白质,它可能成为肺癌患者潜在的治疗药物靶点。